Cardiopulmonary Genomics Program, Department of Medicine, University of Maryland School of Medicine, Baltimore, 21201, USA.
Am J Respir Cell Mol Biol. 2011 Nov;45(5):1069-74. doi: 10.1165/rcmb.2011-0061OC. Epub 2011 Jun 3.
Bitter taste receptors (TAS2Rs) were shown to be expressed in human airway smooth muscle (ASM). They couple to specialized Ca(2+) release, leading to membrane hyperpolarization, the relaxation of ASM, and marked bronchodilation. TAS2Rs are G-protein-coupled receptors, known to undergo rapid agonist-promoted desensitization that can limit therapeutic efficacy. Because TAS2Rs represent a new drug target for treating obstructive lung disease, we investigated their capacity for rapid desensitization, and assessed their potential mechanisms. The pretreatment of human ASM cells with the prototypic TAS2R agonist quinine resulted in a 31% ± 5.1% desensitization of the Ca(2+) response from a subsequent exposure to quinine. No significant change in the endothelin-stimulated Ca(2+) response was attributed to the short-term use of quinine, indicating a homologous form of desensitization. The TAS2R agonist saccharin also evoked desensitization, and cross-compound desensitization with quinine was evident. Desensitization of the Ca(2+) response was attenuated by a dynamin inhibitor, suggesting that receptor internalization (a G-protein coupled receptor kinase [GRK]-mediated, β-arrestin-mediated process) plays an integral role in the desensitization of TAS2R. Desensitization was insensitive to antagonists of the second messenger kinases protein kinase A and protein kinase C. Using intact airways, short-term, agonist-promoted TAS2R desensitization of the relaxation response was also observed. Thus these receptors, which represent a potential novel target for direct bronchodilators, undergo a modest degree of agonist-promoted desensitization that may affect clinical efficacy. Collectively, the results of these mechanistic studies, along with the multiple serines and threonines in intracellular loop 3 and the cytoplasmic tail of TAS2Rs, suggest a GRK-mediated mode of desensitization.
苦味受体(TAS2R)已被证明在人类气道平滑肌(ASM)中表达。它们与专门的[Ca2+](i)释放偶联,导致膜超极化,ASM 松弛,显著支气管扩张。TAS2R 是 G 蛋白偶联受体,已知会发生快速激动剂促进脱敏,从而限制治疗效果。由于 TAS2R 是治疗阻塞性肺部疾病的新药物靶点,我们研究了它们快速脱敏的能力,并评估了它们的潜在机制。用原型 TAS2R 激动剂奎宁预处理人 ASM 细胞,导致随后暴露于奎宁时[Ca2+](i)反应的 31%±5.1%脱敏。由于短期使用奎宁,内皮素刺激的[Ca2+](i)反应没有明显变化,表明存在同源脱敏形式。TAS2R 激动剂糖精也引起脱敏,并且与奎宁的交叉化合物脱敏明显。[Ca2+](i)反应的脱敏作用被一种动力蛋白抑制剂减弱,表明受体内化(一种 G 蛋白偶联受体激酶[GRK]-介导、β-抑制蛋白介导的过程)在 TAS2R 的脱敏中起着重要作用。脱敏对第二信使激酶蛋白激酶 A 和蛋白激酶 C 的拮抗剂不敏感。在完整的气道中,也观察到短期激动剂促进 TAS2R 松弛反应的脱敏作用。因此,这些受体代表了潜在的新型直接支气管扩张剂靶点,它们会发生适度的激动剂促进脱敏,这可能会影响临床疗效。综上所述,这些机制研究的结果,以及 TAS2R 细胞内环 3 和细胞质尾部的多个丝氨酸和苏氨酸,表明存在 GRK 介导的脱敏模式。